Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | EED | O75530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24484595 | 0.87 | HPGD (0.53) | HPGDRECQLEPHX1GPR119MAPT | |
| SCHEMBL6974258 | 0.86 | HPGD (0.55) | HPGDRECQLEPHX1GPR119MAPT | |
| SCHEMBL4546601 | 0.86 | HPGD (0.55) | HPGDRECQLEPHX1GPR119MAPT | |
| SCHEMBL5341723 | 0.85 | HPGD (0.54) | HPGDRECQLEPHX1GPR119MAPT | |
| SCHEMBL470530 | 0.85 | HPGD (0.54) | HPGDRECQLEPHX1GPR119MAPT | |
| SCHEMBL387237 | 0.85 | HPGD (0.54) | HPGDRECQLEPHX1GPR119MAPT | |
| SCHEMBL4523020 | 0.85 | HPGD (0.54) | HPGDRECQLEPHX1GPR119MAPT | |
| SCHEMBL19450523 | 0.83 | HPGD (0.53) | HPGDRECQLEPHX1GPR119MAPT | |
| SCHEMBL8495308 | 0.83 | HPGD (0.53) | HPGDRECQLEPHX1GPR119MAPT | |
| SCHEMBL2258037 | 0.83 | DPP4 (0.54) | HPGDRECQLEPHX1GPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3096754-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015112441-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6211183-B1 | PIPERAZINE DERIVATIVE ANTICOAGULANTS; ANTIISCHEMIC AGENTS; CARDIOVASCULAR DISORDERS | COR THERAPEUTICS, INC. | 2001-04-03 | — | — | US | disclosed |
| EP-0975625-A1 | SELECTIVE FACTOR Xa INHIBITORS | COR THERAPEUTICS, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| EP-0512831-B1 | Fibrinogen receptor antagonists | MERCK & CO INC (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998046591-A1 | SELECTIVE FACTOR Xa INHIBITORS | COR THERAPEUTICS, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5455243-A | Anticoagulants | MERCK & CO., INC. (US) | 1995-10-03 | — | — | US | disclosed |
| US-5281585-A | Secondary amide containing antagonist | MERCK & CO., INC. (US) | 1994-01-25 | — | — | US | disclosed |
| CN-1067883-A | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1993-01-13 | — | — | CN | disclosed |
| EP-0512831-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | HPGD 4285/4885RECQL 4243/4885EPHX1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.